Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI

Published:2017-05-04 Issue:3 Volume:18 Page:118-125
ISSN:1528-4336
Container-title:HIV Clinical Trials
language:en
Short-container-title:HIV Clinical Trials

Author:

Arribas Jose R.¹,DeJesus Edwin²,van Lunzen Jan³,Zurawski Christine⁴,Doroana Manuela⁵,Towner William⁶,Lazzarin Adriano⁷,Nelson Mark⁸,McColl Damian⁹,Andreatta Kristen⁹,Swamy Raji⁹,Szwarcberg Javier⁹,Nguyen Thai⁹

Affiliation:

1. Hospital Universitario La Paz, IdiPAZ, Madrid, Spain

2. Orlando Immunology Center, Orlando FL, USA

3. Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany

4. Atlanta ID Group, Atlanta GA, USA

5. Hospital de Santa Maria, Lisbon, Portugal

6. Southern California Kaiser Permanente Medical Group, Los Angeles CA, USA

7. Fondazione IRCCS San Raffaele del Monte Tabor, Milan, Italy

8. Chelsea and Westminster Hospital, London, UK

9. Gilead Sciences, Inc., Foster City, CA, USA

Funder

Gilead Sciences

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases

Link

https://www.tandfonline.com/doi/pdf/10.1080/15284336.2017.1330440

Reference29 articles.

1. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people

2. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV

3. Adherence to Antiretroviral Treatment and Correlation with Risk of Hospitalization among Commercially Insured HIV Patients in the United States

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reasons, safety and efficacy analysis for conversion of HAART to TAF/FTC/BIC among HIV-infected patients;Chinese Medical Journal;2023-11-29

2. Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study;AIDS Research and Therapy;2023-01-03

3. A pharmacogenetic study in HIV-infected patients treated with ritonavir: hematological and cardiovascular disease risk analysis;Minerva Biotechnology and Biomolecular Research;2022-01

4. Using a single tablet regimen of darunavir, cobicistat, emcitrabine, and tenofovir alafenamide in virally suppressed HIV-1 patients is an adequate treatment option for controlling HIV;Clinical Research In Practice: The Journal of Team Hippocrates;2021-10-13

5. Integrase strand transfer inhibitors can simplify HIV treatment;Drugs & Therapy Perspectives;2021-06-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3